UY38010A - Anticuerpos de alfa-sinucleína y sus usos - Google Patents

Anticuerpos de alfa-sinucleína y sus usos

Info

Publication number
UY38010A
UY38010A UY0001038010A UY38010A UY38010A UY 38010 A UY38010 A UY 38010A UY 0001038010 A UY0001038010 A UY 0001038010A UY 38010 A UY38010 A UY 38010A UY 38010 A UY38010 A UY 38010A
Authority
UY
Uruguay
Prior art keywords
antibodies
alpha
synuclein
sinucleine
alfa
Prior art date
Application number
UY0001038010A
Other languages
English (en)
Inventor
Ralph Adams
Kerry Louise Tyson
Daniel John Lightwood
Patrick Downey
Terence Seward Baker
Lichtervelde Lorenzo De
David James Mcmillan
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of UY38010A publication Critical patent/UY38010A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a anticuerpos que se unen a alfa–sinucleína y a sus fragmentos capaces de unirse a alfa–sinucleína como monómero y en fibrillas y a la prevención de la agregación de alfa–sinucleína inducida por fibrillas de alfa–sinucleína. Los anticuerpos de la presente invención son para usar en el tratamiento de alfa–sinucleinopatías, incluida la enfermedad de Parkinson.
UY0001038010A 2017-12-15 2018-12-14 Anticuerpos de alfa-sinucleína y sus usos UY38010A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1720975.0A GB201720975D0 (en) 2017-12-15 2017-12-15 Anti-alpha synuclein antibodies

Publications (1)

Publication Number Publication Date
UY38010A true UY38010A (es) 2019-07-31

Family

ID=61009086

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038010A UY38010A (es) 2017-12-15 2018-12-14 Anticuerpos de alfa-sinucleína y sus usos

Country Status (24)

Country Link
US (2) US11261242B2 (es)
EP (1) EP3724224A1 (es)
JP (2) JP7292279B2 (es)
KR (1) KR20200099160A (es)
AR (1) AR115192A1 (es)
AU (1) AU2018382530A1 (es)
BR (1) BR112020010504A2 (es)
CA (1) CA3083199A1 (es)
CL (1) CL2020001605A1 (es)
EA (1) EA202091478A1 (es)
EC (1) ECSP20039623A (es)
GB (1) GB201720975D0 (es)
IL (1) IL275187A (es)
MA (1) MA51135A (es)
MX (1) MX2020005691A (es)
PE (1) PE20201061A1 (es)
PH (1) PH12020551007A1 (es)
SG (1) SG11202004502SA (es)
TN (2) TN2020000069A1 (es)
TW (2) TW202332692A (es)
UA (1) UA126295C2 (es)
UY (1) UY38010A (es)
WO (1) WO2019115674A1 (es)
ZA (2) ZA202003542B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
EA202190807A1 (ru) * 2018-10-19 2021-08-06 Янссен Вэксинс Энд Превеншн Б.В. Антитела к синуклеину
WO2021055881A1 (en) * 2019-09-20 2021-03-25 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof
US20230025256A1 (en) * 2019-12-04 2023-01-26 Simon Friedman Protein blocking assembly and methods of making and using

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2002050121A1 (fr) 2000-12-13 2002-06-27 Taisho Pharmaceutical Co.,Ltd. Nouvel anticorps
CA2466841A1 (en) 2001-11-21 2003-06-05 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid .beta., prion protein, amylin, .alpha.-synuclein, or polyglutamine repeats for induction of an immune response thereto
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
SI2361928T1 (sl) 2003-05-19 2017-07-31 Prothena Biosciences Limited Skrajšani fragmenti alfa-sinukleina pri bolezni Lewyjevih telesc
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
WO2007021255A1 (en) 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP2118300B1 (en) 2007-02-23 2015-05-27 Prothena Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
ES2546863T3 (es) 2007-02-23 2015-09-29 Prothena Biosciences Limited Prevención y tratamiento de enfermedad sinucleinopática y amiloidogénica
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
EP2539366B1 (en) 2010-02-26 2017-11-08 BioArtic Neuroscience AB Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
US20160077112A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of Misfolded Proteins
US9910049B2 (en) 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
US10989718B2 (en) 2014-09-11 2021-04-27 Amprion, Inc. Detection of misfolded alpha synuclein protein
JP5980790B2 (ja) 2010-11-05 2016-08-31 ブランダイス ユニバーシティＢｒａｎｄｅｉｓ Ｕｎｉｖｅｒｓｉｔｙ バイオマーカーとしての、ｉｃｅ切断されたアルファ−シヌクレイン
DE102011008153B4 (de) 2011-01-08 2018-08-09 Aj Roboscreen Gmbh Verfahren zur Herstellung eines monoklonalen Antikörpers gegen oligomeres Alpha-Synuclein
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
KR101600733B1 (ko) * 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
ES2856272T3 (es) 2012-05-30 2021-09-27 Chugai Pharmaceutical Co Ltd Molécula de unión a antígenos para eliminar antígenos agregados
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US9534044B2 (en) * 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
EP3071974A2 (en) 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
RU2697098C1 (ru) 2013-11-21 2019-08-12 Ф.Хоффманн-Ля Рош Аг Антитела к альфа-синуклеину и способы применения
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10155030B2 (en) 2014-05-23 2018-12-18 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinsons disease
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017033152A1 (en) 2015-08-25 2017-03-02 Prothena Biosciences Limited Methods for detecting phosphorylated alpha-synuclein
JP6976249B2 (ja) 2015-11-23 2021-12-08 サンガモ セラピューティクス， インコーポレイテッド 免疫を工学操作するための方法および組成物
EP3440225A4 (en) 2016-04-06 2020-03-11 Imago Pharmaceuticals, Inc. THERAPEUTIC ANTIBODIES FOR TREATING NEURODEGENERATION
UA124733C2 (uk) 2016-06-02 2021-11-10 Медімм'Юн Лімітед Антитіло до альфа-синуклеїну
GB201611840D0 (en) 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
WO2018039147A1 (en) 2016-08-23 2018-03-01 The Johns Hopkins University THERAPEUTIC USES OF LAG3 THE α-SYNUCLEIN TRANSMISSION RECEPTOR
WO2018091444A1 (en) 2016-11-15 2018-05-24 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
US20180134777A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (11D12)
US20180134775A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (7A11)
US20180134776A1 (en) 2016-11-17 2018-05-17 United Arab Emirates University Alpha-Synuclein Antibodies (4H6)
EP3551228A4 (en) 2016-12-12 2020-08-12 The Michael J. Fox Foundation For Parkinson's Research ANTIBODIES FOR HUMAN ALPHA SYNUCLEIN
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
EP3565636B1 (en) 2017-01-09 2024-01-03 California Institute of Technology Use of gut microbiota in the diagnosis of parkinson's disease
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
JOP20190227A1 (ar) 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
EP3635393A4 (en) 2017-05-16 2021-03-10 Claudio Soto-Jara DETECTION OF MISFOLDED TAU PROTEIN
WO2018237338A1 (en) 2017-06-23 2018-12-27 Denali Therapeutics Inc. ANTI-ALPHA-SYNCUCIN ANTIBODIES AND METHODS OF USE

Also Published As

Publication number Publication date
PH12020551007A1 (en) 2021-08-16
US20220220192A1 (en) 2022-07-14
EA202091478A1 (ru) 2020-09-04
CL2020001605A1 (es) 2020-08-28
RU2020123274A3 (es) 2022-01-17
US20210107971A1 (en) 2021-04-15
MA51135A (fr) 2021-03-24
JP2023127585A (ja) 2023-09-13
ZA202103456B (en) 2023-01-25
TN2021000169A1 (en) 2023-04-04
EP3724224A1 (en) 2020-10-21
ECSP20039623A (es) 2020-08-31
GB201720975D0 (en) 2018-01-31
BR112020010504A2 (pt) 2020-11-24
UA126295C2 (uk) 2022-09-14
AU2018382530A1 (en) 2020-06-18
RU2020123274A (ru) 2022-01-17
CN111479826A (zh) 2020-07-31
CA3083199A1 (en) 2019-06-20
TWI801469B (zh) 2023-05-11
JP2021509012A (ja) 2021-03-18
TW201930354A (zh) 2019-08-01
WO2019115674A1 (en) 2019-06-20
KR20200099160A (ko) 2020-08-21
TW202332692A (zh) 2023-08-16
PE20201061A1 (es) 2020-10-16
ZA202003542B (en) 2022-12-21
TN2020000069A1 (en) 2022-01-06
AR115192A1 (es) 2020-12-09
US11261242B2 (en) 2022-03-01
IL275187A (en) 2020-07-30
MX2020005691A (es) 2020-08-20
JP7292279B2 (ja) 2023-06-16
SG11202004502SA (en) 2020-06-29

Similar Documents

Publication Publication Date Title
UY38012A (es) Anticuerpos de alfa-sinucleína y sus usos
CR20230477A (es) MOLÉCULAS DE ANTICUERPO QUE SE UNEN A CD73 Y USOS DE LAS MISMAS (Divisional Exp. 2019-0593)
UY38010A (es) Anticuerpos de alfa-sinucleína y sus usos
CO2017003048A2 (es) Moléculas de unión a antígeno biespecíficas activadoras de células t que se unen a cd3 y al receptor 1 de folato (folr1)
CL2020001637A1 (es) Anticuerpos para lilrb2
CO2017005240A2 (es) Inmunoglobulinas hetero-diméricas de redireccionamiento de células t cd3/cd38 y sus métodos de producción
GT201700033A (es) Anticuerpos anti tigit
ECSP19020740A (es) Anticuerpos anti-cd27
ECSP19029758A (es) Anticuerpos anti-il-33 y usos de los mismos
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
AR102658A1 (es) Composición para el tratamiento de telas
NI201800134A (es) Anticuerpos antifactor de la coagulación xi
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
PE20170258A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CL2020001629A1 (es) Anticuerpos de unión a hla-a2/wt1.
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MX2020009130A (es) Anticuerpos terapéuticos anti-spla2-gib y los usos de los mismos.
CL2019002735A1 (es) Anticuerpos que se unen a steap-1.
AR114808A1 (es) ANTICUERPOS ANTI-a-SINUCLEÍNA
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
AR119639A1 (es) Moléculas de anticuerpo para cd73 y sus usos
AR120118A2 (es) Anticuerpos anti tigit

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114